Amgen gets a no from the FDA on extended use of Xgeva

The FDA told Amgen ($AMGN) no to an expanded use of its cancer treatment Xgeva, one of the company's most important drugs, saying the company could try again with more data. The drug is already ap…
Read the full story: News